TY - JOUR
T1 - Gonadotroph adenoma of the pituitary gland
T2 - a clinicopathologic analysis of 100 cases
AU - Young, William F.
AU - Scheithaler, Bernd W.
AU - Kovacs, Kalman T.
AU - Horvath, Eva
AU - Davis, Dudley H.
AU - Randall, Raymond V.
N1 - Funding Information:
This work was supported in part by the generous contributions of Mr. and Mrs. Francis A. Wittern, Sr., Mr. and Mrs. Francis A. Wittem, Jr., Mr. and Mrs. Jarislowski, and the Lloyd Carr-Harris Foundation.
PY - 1996
Y1 - 1996
N2 - Objective: To determine the clinical and pathologic features in a large cohort of randomly selected patients with gonadotroph pituitary adenomas. Design: We retrospectively reviewed clinical, surgical, and pathologic findings in 100 patients (79 men and 21 women, 30 to 82 years old) with this tumor. Results: Diagnosis of a pituitary tumor was prompted by visual loss (43%), symptoms of hypopituitaristn (22%), headache (8%), or a combination of these findings (10%); 17% of the patients were asymptomatic. Visual field defects were present in 68% of the study group, and complete or partial anterior pituitary failure was present in 77%. Serum prolactin concentrations were increased (maximum, 110 ng/mL) in 33% of patients. Hypersécrétion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) was documented in 11 and 5 patients, respectively. The serum level of a-subunit was increased in 1 of 29 patients in whom it was measured. All patients had pituitary macroadenomas, only 21% of which were grossly invasive. The surgical approach was transsphenoidal in all but two patients, who underwent transfrontal craniotomy; gross total tumor resection was achieved in 90%. By definition, all tumors had at least 10% immunoreactivity for LH, FSH, or both. All tumors were chromophobic. Ultrastructurally, the tumors were characterized as gonadotroph adenomas of "male" (45%) or "female" (9%) type as well as null-cell adenomas of the oncocytic (35%) or nononcocytic (11%) type. After a median follow-up of 4.3 years, 69% of the patients who had had visual field defects noted normalization or improvement. Persistent or clinically recurrent pituitary tumor tissue was present in 42%. A second pituitary surgical procedure was required in eight patients. Conclusion: Most patients with clinically evident gonadotroph pituitary tumors have loss of vision and hypopituitarism. Hypersécrétion of FSH or LH is unusual, and no distinct hormone-dependent clinical phenotype is present. Transsphenoidal surgical treatment generally yields normalization or improvement of visual field defects.
AB - Objective: To determine the clinical and pathologic features in a large cohort of randomly selected patients with gonadotroph pituitary adenomas. Design: We retrospectively reviewed clinical, surgical, and pathologic findings in 100 patients (79 men and 21 women, 30 to 82 years old) with this tumor. Results: Diagnosis of a pituitary tumor was prompted by visual loss (43%), symptoms of hypopituitaristn (22%), headache (8%), or a combination of these findings (10%); 17% of the patients were asymptomatic. Visual field defects were present in 68% of the study group, and complete or partial anterior pituitary failure was present in 77%. Serum prolactin concentrations were increased (maximum, 110 ng/mL) in 33% of patients. Hypersécrétion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) was documented in 11 and 5 patients, respectively. The serum level of a-subunit was increased in 1 of 29 patients in whom it was measured. All patients had pituitary macroadenomas, only 21% of which were grossly invasive. The surgical approach was transsphenoidal in all but two patients, who underwent transfrontal craniotomy; gross total tumor resection was achieved in 90%. By definition, all tumors had at least 10% immunoreactivity for LH, FSH, or both. All tumors were chromophobic. Ultrastructurally, the tumors were characterized as gonadotroph adenomas of "male" (45%) or "female" (9%) type as well as null-cell adenomas of the oncocytic (35%) or nononcocytic (11%) type. After a median follow-up of 4.3 years, 69% of the patients who had had visual field defects noted normalization or improvement. Persistent or clinically recurrent pituitary tumor tissue was present in 42%. A second pituitary surgical procedure was required in eight patients. Conclusion: Most patients with clinically evident gonadotroph pituitary tumors have loss of vision and hypopituitarism. Hypersécrétion of FSH or LH is unusual, and no distinct hormone-dependent clinical phenotype is present. Transsphenoidal surgical treatment generally yields normalization or improvement of visual field defects.
UR - http://www.scopus.com/inward/record.url?scp=0030317106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030317106&partnerID=8YFLogxK
U2 - 10.4065/71.7.649
DO - 10.4065/71.7.649
M3 - Article
C2 - 8656706
AN - SCOPUS:0030317106
SN - 0025-6196
VL - 71
SP - 649
EP - 656
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 7
ER -